CoChat
Sign Up
Cited by 931Heart Failure Treatment and ManagementCardiovascular Function and Risk FactorsHeart rate and cardiovascular health

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary

Open access
Heidenreich, Paul A., Bozkurt, Biykem, Aguilar, David, Allen, Larry A., Byun, Joni J., Colvin, Monica M., Deswal, Anita, Drazner, Mark H. +18 more·2022·Journal of the American College of Cardiology
DOI 10.1016/j.jacc.2021.12.011
Open this paper in CoChat — free account

Abstract

Aim The "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure" replaces the "2013 ACCF/AHA Guideline for the Management of Heart Failure" and the "2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure." The 2022 guideline is intended to provide patient-centric recommendations for clinicians to prevent, diagnose, and manage patients with heart failure. Methods A comprehensive literature search was conducted from May 2020 to December 2020, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from MEDLINE (PubMed), EMBASE, the Cochrane Collaboration, the Agency for Healthcare Research and Quality, and other relevant databases. Additional relevant clinical trials and research studies, published through September 2021, were also considered. This guideline was harmonized with other American Heart Association/American College of Cardiology guidelines published through December 2021. Structure Heart failure remains a leading cause of morbidity and mortality globally. The 2022 heart failure guideline provides recommendations based on contemporary evidence for the treatment of these patients. The recommendations present an evidence-based approach to managing patients with heart failure, with the intent to improve quality of care and align with patients' interests. Many recommendations from the earlier heart failure guidelines have been updated with new evidence, and new recommendations have been created when supported by published data. Value statements are provided for certain treatments with high-quality published economic analyses.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2021.12.011

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Early detection of structural heart disease improves outcomes, but widespread screening is limited by the cost and accessibility of imaging tools such as echocardiography.

    “Early detection of structural heart disease is critical to improving outcomes, but widespread screening remains limited by the cost and accessibility of imaging tools such as echocardiography1,2.”

    From Detecting structural heart disease from electrocardiograms using AI (2025) · cites this paper as [2]

    Take-Home Message No. 9 (Methods; page unavailable) supports the prevention aspect: it says screening followed by team-based care can help prevent left ventricular dysfunction or new-onset heart failure. It does not say that the cost or accessibility of echocardiography limits widespread screening; searches for those terms found no supporting passage in our copy. (LLM, conf=0.83)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 206

  1. [2]2. Yancy C.W., Jessup M., Bozkurt B., et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 2017;70:776-803. Go to Citation Crossref PubMed Google Scholar
  2. [3]3. Arnett D.K., Blumenthal R.S., Albert M.A., et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019;74:e177-e232. Go to Citation Crossref PubMed Google Scholar
  3. [4]4. Otto C.M., Nishimura R.A., Bonow R.O., et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2021;77:e25-e197. Go to Citation Crossref PubMed Google Scholar
  4. [5]5. Heidenreich P.A., Bozkurt B., Aguilar D., et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol Published online April 1, 2022. https://doi.org/10.1016/j.jacc.2021.12.012. PubMed Google Scholar a [...] of the full clinical practice guideline b [...] should know about the 2022 HF guideline c [...] of the full guideline d [...] of the full guideline · DOI · Paper page
  5. [8]8. Wachter R., Senni M., Belohlavek J., et al. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail 2019;21:998-1007. Crossref PubMed Google Scholar a [...] to reduce morbidity and mortality b [...] to further reduce morbidity and mortality
  6. [10]10. Desai A.S., Solomon S.D., Shah A.M., et al. Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 2019;322:1077-1084. Crossref PubMed Google Scholar a [...] to reduce morbidity and mortality b [...] to further reduce morbidity and mortality
  7. [11]11. Wang Y., Zhou R., Lu C., et al. Effects of the angiotensin-receptor neprilysin inhibitor on cardiac reverse remodeling: meta-analysis. J Am Heart Assoc 2019;8: e012272. Crossref Google Scholar a [...] to reduce morbidity and mortality b [...] to further reduce morbidity and mortality
  8. [12]12. Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-1435. Go to Citation Crossref PubMed Google Scholar
  9. [13]13. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302. Go to Citation Crossref PubMed Google Scholar
  10. [15]15. Pfeffer M.A., Braunwald E., Moyé L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. The SAVE Investigators. N Engl J Med 1992;327:669-677. Crossref PubMed Google Scholar a [...] when the use of ARNi is not feasible b [...] prevent symptomatic HF and reduce mortality
  11. [16]16. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993;342:821-828. Go to Citation PubMed Google Scholar
  12. [17]17. Køber L., Torp-Pedersen C., Carlsen J.E., et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333:1670-1676. Crossref PubMed Google Scholar a [...] when the use of ARNi is not feasible b [...] prevent symptomatic HF and reduce mortality
  13. [18]18. Garg R., Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273:1450-1456. Go to Citation Crossref PubMed Google Scholar
  14. [20]20. Cohn J.N., Tognoni G., Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-1675. Go to Citation Crossref PubMed Google Scholar
  15. [21]21. Pfeffer M.A., McMurray J.J., Velazquez E.J., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-1906. Go to Citation Crossref PubMed Google Scholar
  16. [23]23. ONTARGET Investigators. Yusuf S., Teo K.K., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-1559. Go to Citation Crossref PubMed Google Scholar
  17. [24]24. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008;372:1174-1183. Go to Citation Crossref PubMed Google Scholar
  18. [25]25. Cardiac Insufficiency Authors. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13. Go to Citation Crossref PubMed Google Scholar
  19. [26]26. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-2007. Go to Citation Crossref PubMed Google Scholar
  20. [27]27. Packer M., Fowler M.B., Roecker E.B., et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002;106:2194-2199. Go to Citation Crossref PubMed Google Scholar
  21. [29]29. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321. Go to Citation Crossref PubMed Google Scholar
  22. [33]33. Anker S.D., Butler J., Filippatos G., et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451-1461. Crossref PubMed Google Scholar a [...] and cardiovascular mortality b [...] and cardiovascular mortality
  23. [34]34. Cleland J.G.F., Bunting K.V., Flather M.D., et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J 2018;39:26-35. Go to Citation Crossref PubMed Google Scholar
  24. [35]35. Solomon S.D., McMurray J.J.V., Anand I.S., et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019;381:1609-1620. Crossref PubMed Google Scholar a [...] with LVEF on the lower end of this spectrum b [...] with LVEF on the lower end of this spectrum
  25. [36]36. Halliday B.P., Wassall R., Lota A.S., et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet 2019;393:61-73. Crossref PubMed Google Scholar a [...] with LVEF on the lower end of this spectrum b [...] in patients who may become asymptomatic
  26. [37]37. Nilsson B.B., Lunde P., Grogaard H.K., et al. Long-term results of high-intensity exercise-based cardiac rehabilitation in revascularized patients for symptomatic coronary artery disease. Am J Cardiol 2018;121:21-26. Go to Citation Crossref PubMed Google Scholar
  27. [38]38. Solomon S.D., Claggett B., Desai A.S., et al. Influence of ejection fraction on outcomes and efficacy of sacubitril/valsartan (lcz696) in heart failure with reduced ejection fraction: the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial. Circ Heart Fail 2016;9: e002744. Crossref Google Scholar a [...] with LVEF on the lower end of this spectrum b [...] with LVEF on the lower end of this spectrum
  28. [39]39. Tsuji K., Sakata Y., Nochioka K., et al. Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study. Eur J Heart Fail 2017;19:1258-1269. Go to Citation Crossref PubMed Google Scholar
  29. [40]40. Solomon S.D., Vaduganathan M., al CBLe Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation 2020;141:352-361. Crossref PubMed Google Scholar a [...] with LVEF on the lower end of this spectrum b [...] with LVEF on the lower end of this spectrum
  30. [41]41. Zheng S.L., Chan F.T., Nabeebaccus A.A., et al. Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart 2018;104:407-415. Go to Citation Crossref PubMed Google Scholar
  31. [42]42. Pitt B., Pfeffer M.A., Assmann S.F., et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014;370:1383-1392. Go to Citation Crossref PubMed Google Scholar
  32. [43]43. Pfeffer M.A., Claggett B., Assmann S.F., et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 2015;131:34-42. Go to Citation Crossref PubMed Google Scholar
  33. [44]44. Thomopoulos C., Parati G., Zanchetti A. Effects of blood-pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs: meta-analyses of randomized trials. J Hypertens 2016;34:1921-1932. Go to Citation Crossref PubMed Google Scholar
  34. [45]45. Williamson J.D., Supiano M.A., Applegate W.B., et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial. JAMA 2016;315:2673-2682. Go to Citation Crossref PubMed Google Scholar
  35. [46]46. SPRINT Research Group, Wright J.T. Jr., Williamson J.D., et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103-2116. Crossref PubMed Google Scholar a [...] practice guidelines to prevent morbidity b [...] for hypertension to prevent symptomatic HF
  36. [47]47. Yusuf S., Pfeffer M.A., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777-781. Go to Citation Crossref PubMed Google Scholar
  37. [48]48. Lund L.H., Claggett B., Liu J., et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail 2018;20:1230-1239. Go to Citation Crossref PubMed Google Scholar
  38. [49]49. Redfield M.M., Anstrom K.J., Levine J.A., et al. Isosorbide mononitrate in heart failure with preserved ejection fraction. N Engl J Med 2015;373:2314-2324. Go to Citation Crossref PubMed Google Scholar
  39. [50]50. Redfield M.M., Chen H.H., Borlaug B.A., et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013;309:1268-1277. Go to Citation Crossref PubMed Google Scholar
  40. [51]51. Anderson J.L., Heidenreich P.A., Barnett P.G., et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2304-2322. Go to Citation Crossref PubMed Google Scholar
  41. [52]52. Banka G., Heidenreich P.A., Fonarow G.C. Incremental cost-effectiveness of guideline-directed medical therapies for heart failure. J Am Coll Cardiol 2013;61:1440-1446. Crossref PubMed Google Scholar a [...] an ACEi or ARB provides high economic value b [...] therapy provides high economic value c [...] MRA therapy provides high economic value
  42. [53]53. Dasbach E.J., Rich M.W., Segal R., et al. The cost-effectiveness of losartan versus captopril in patients with symptomatic heart failure. Cardiology 1999;91:189-194. Go to Citation Crossref PubMed Google Scholar
  43. [54]54. Glick H., Cook J., Kinosian B., et al. Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial. J Card Fail 1995;1:371-380. Go to Citation Crossref PubMed Google Scholar
  44. [55]55. Paul S.D., Kuntz K.M., Eagle K.A., et al. Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure. Arch Intern Med 1994;154:1143-1149. Go to Citation Crossref PubMed Google Scholar
  45. [56]56. Reed S.D., Friedman J.Y., Velazquez E.J., et al. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2004;148:122-128. Go to Citation Crossref PubMed Google Scholar
  46. [58]58. Tsevat J., Duke D., Goldman L., et al. Cost-effectiveness of captopril therapy after myocardial infarction. J Am Coll Cardiol 1995;26:914-919. Go to Citation Crossref PubMed Google Scholar
  47. [59]59. Gaziano T.A., Fonarow G.C., Claggett B., et al. Cost-effectiveness analysis of Sacubitril/valsartan vs enalapril in patients with heart failure and reduced ejection fraction. JAMA Cardiol 2016;1:666-672. Go to Citation Crossref PubMed Google Scholar
  48. [60]60. Gaziano T.A., Fonarow G.C., Velazquez E.J., et al. Cost-effectiveness of sacubitril-valsartan in hospitalized patients who have heart failure with reduced ejection fraction. JAMA Cardiol 2020;5:1236-1244. Go to Citation Crossref PubMed Google Scholar
  49. [61]61. King J.B., Shah R.U., Bress A.P., et al. Cost-effectiveness of sacubitril-valsartan combination therapy compared with enalapril for the treatment of heart failure with reduced ejection fraction. J Am Coll Cardiol HF 2016;4:392-402. Go to Citation Google Scholar
  50. [62]62. Sandhu A.T., Goldhaber-Fiebert J.D., Owens D.K., et al. Cost-effectiveness of implantable pulmonary artery pressure monitoring in chronic heart failure. J Am Coll Cardiol HF 2016;4:368-375. Google Scholar a [...] of an ACEi provides high economic value b [...] monitor provides uncertain value
  51. [63]63. Caro J.J., Migliaccio-Walle K., O'Brien J.A., et al. Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial: a US perspective of the MERIT-HF trial. J Card Fail 2005;11:647-656. Go to Citation Crossref PubMed Google Scholar
  52. [64]64. Delea T.E., Vera-Llonch M., Richner R.E., et al. Cost effectiveness of carvedilol for heart failure. Am J Cardiol 1999;83:890-896. Go to Citation Crossref PubMed Google Scholar
  53. [66]66. Vera-Llonch M., Menzin J., Richner R.E., et al. Cost-effectiveness results from the US Carvedilol Heart Failure Trials Program. Ann Pharmacother 2001;35:846-851. Go to Citation Crossref PubMed Google Scholar
  54. [67]67. Glick H.A., Orzol S.M., Tooley J.F., et al. Economic evaluation of the randomized aldactone evaluation study (RALES): treatment of patients with severe heart failure. Cardiovasc Drugs Ther 2002;16:53-59. Go to Citation Crossref PubMed Google Scholar
  55. [68]68. Weintraub W.S., Zhang Z., Mahoney E.M., et al. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation 2005;111:1106-1113. Go to Citation Crossref PubMed Google Scholar
  56. [69]69. Zhang Z., Mahoney E.M., Kolm P., et al. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS. Am J Cardiovasc Drugs 2010;10:55-63. Go to Citation Crossref PubMed Google Scholar
  57. [70]70. Angus D.C., Linde-Zwirble W.T., Tam S.W., et al. Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure. Circulation 2005;112:3745-3753. Go to Citation Crossref PubMed Google Scholar
  58. [71]71. Al-Khatib S.M., Anstrom K.J., Eisenstein E.L., et al. Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II. Ann Intern Med 2005;142:593-600. Go to Citation Crossref PubMed Google Scholar
  59. [72]72. Cowie M.R., Marshall D., Drummond M., et al. Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population. Europace 2009;11:716-726. Go to Citation Crossref PubMed Google Scholar
  60. [73]73. Mark D.B., Nelson C.L., Anstrom K.J., et al. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation 2006;114:135-142. Go to Citation Crossref PubMed Google Scholar
  61. [74]74. Mushlin A.I., Hall W.J., Zwanziger J., et al. The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Multicenter Automatic Defibrillator Implantation Trial. Circulation 1998;97:2129-2135. Go to Citation Crossref PubMed Google Scholar
  62. [75]75. Sanders G.D., Hlatky M.A., Owens D.K. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 2005;353:1471-1480. Go to Citation Crossref PubMed Google Scholar
  63. [76]76. Zwanziger J., Hall W.J., Dick A.W., et al. The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 2006;47:2310-2318. Go to Citation Crossref PubMed Google Scholar
  64. [77]77. Feldman A.M., de Lissovoy G., Bristow M.R., et al. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol 2005;46:2311-2321. Go to Citation Crossref PubMed Google Scholar
  65. [78]78. Gold M.R., Padhiar A., Mealing S., et al. Economic value and cost-effectiveness of cardiac resynchronization therapy among patients with mild heart failure: projections from the REVERSE long-term follow-up. J Am Coll Cardiol HF 2017;5:204-212. Go to Citation Google Scholar
  66. [79]79. Heerey A., Lauer M., Alsolaiman F., et al. Cost effectiveness of biventricular pacemakers in heart failure patients. Am J Cardiovasc Drugs 2006;6:129-137. Go to Citation Crossref PubMed Google Scholar
  67. [80]80. Nichol G., Kaul P., Huszti E., et al. Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure. Ann Intern Med 2004;141:343-351. Go to Citation Crossref PubMed Google Scholar
  68. [81]81. Noyes K., Veazie P., Hall W.J., et al. Cost-effectiveness of cardiac resynchronization therapy in the MADIT-CRT trial. J Cardiovasc Electrophysiol 2013;24:66-74. Go to Citation Crossref PubMed Google Scholar
  69. [82]82. Woo C.Y., Strandberg E.J., Schmiegelow M.D., et al. Cost-effectiveness of adding cardiac resynchronization therapy to an implantable cardioverter-defibrillator among patients with mild heart failure. Ann Intern Med 2015;163:417-426. Go to Citation Crossref PubMed Google Scholar
  70. [83]83. Parizo J.T., Goldhaber-Fiebert J.D., Salomon J.A., et al. Cost-effectiveness of dapagliflozin for treatment of patients with heart failure with reduced ejection fraction. JAMA Cardiol 2021;6:926-935. Go to Citation Crossref PubMed Google Scholar
  71. [84]84. Isaza N., Calvachi P., Raber I., et al. Cost-effectiveness of dapagliflozin for the treatment of heart failure with reduced ejection fraction. JAMA Netw Open 2021;4: e2114501. Go to Citation Crossref PubMed Google Scholar
  72. [85]85. Long E.F., Swain G.W., Mangi A.A. Comparative survival and cost-effectiveness of advanced therapies for end-stage heart failure. Circ Heart Fail 2014;7:470-478. Crossref PubMed Google Scholar a [...] provides intermediate economic value b [...] value based on current costs and outcomes
  73. [86]86. Kazi D.S., Bellows B.K., Baron S.J., et al. Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy. Circulation 2020;141:1214-1224. Go to Citation Crossref PubMed Google Scholar
  74. [87]87. Baras Shreibati J., Goldhaber-Fiebert J.D., Banerjee D., et al. Cost-effectiveness of left ventricular assist devices in ambulatory patients with advanced heart failure. J Am Coll Cardiol HF 2017;5:110-119. Go to Citation Google Scholar
  75. [88]88. Mahr C., McGee E. Jr., Cheung A., et al. Cost-effectiveness of thoracotomy approach for the implantation of a centrifugal left ventricular assist device. ASAIO J 2020;66:855-861. Go to Citation Crossref PubMed Google Scholar
  76. [89]89. Rogers J.G., Bostic R.R., Tong K.B., et al. Cost-effectiveness analysis of continuous-flow left ventricular assist devices as destination therapy. Circ Heart Fail 2012;5:10-16. Go to Citation Crossref PubMed Google Scholar
  77. [90]90. Silvestry S.C., Mahr C., Slaughter M.S., et al. Cost-effectiveness of a small intrapericardial centrifugal left ventricular assist device. ASAIO J 2020;66:862-870. Go to Citation Crossref PubMed Google Scholar
  78. [91]91. Martinson M., Bharmi R., Dalal N., et al. Pulmonary artery pressure-guided heart failure management: US cost-effectiveness analyses using the results of the CHAMPION clinical trial. Eur J Heart Fail 2017;19:652-660. Go to Citation Crossref PubMed Google Scholar
  79. [92]92. Schmier J.K., Ong K.L., Fonarow G.C. Cost-effectiveness of remote cardiac monitoring with the cardiomems heart failure system. Clin Cardiol 2017;40:430-436. Go to Citation Crossref PubMed Google Scholar
  80. [93]93. Lindenfeld J., Zile M.R., Desai A.S., et al. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. Lancet 2021;398:991-1001. Go to Citation Crossref PubMed Google Scholar
  81. [94]94. Castano A., Narotsky D.L., Hamid N., et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J 2017;38:2879-2887. Go to Citation Crossref PubMed Google Scholar
  82. [95]95. Gonzalez-Lopez E., Gallego-Delgado M., Guzzo-Merello G., et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015;36:2585-2594. Go to Citation Crossref PubMed Google Scholar
  83. [96]96. Sperry B.W., Reyes B.A., Ikram A., et al. Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release. J Am Coll Cardiol 2018;72:2040-2050. Go to Citation Crossref PubMed Google Scholar
  84. [97]97. Westermark P., Westermark G.T., Suhr O.B., et al. Transthyretin-derived amyloidosis: probably a common cause of lumbar spinal stenosis. Ups J Med Sci 2014;119:223-228. Go to Citation Crossref PubMed Google Scholar
  85. [98]98. Maurer M.S., Hanna M., Grogan M., et al. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol 2016;68:161-172. Go to Citation Crossref PubMed Google Scholar
  86. [99]99. Muchtar E., Gertz M.A., Kyle R.A., et al. A modern primer on light chain amyloidosis in 592 patients with mass spectrometry-verified typing. Mayo Clin Proc 2019;94:472-483. Go to Citation PubMed Google Scholar
  87. [100]100. Gillmore J.D., Maurer M.S., Falk R.H., et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404-2412. Go to Citation Crossref PubMed Google Scholar
  88. [101]101. Brown E.E., Lee Y.Z.J., Halushka M.K., et al. Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis. Amyloid 2017;24:92-95. Go to Citation Crossref PubMed Google Scholar
  89. [102]102. Maurer M.S., Schwartz J.H., Gundapaneni B., et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018;379:1007-1016. Go to Citation Crossref PubMed Google Scholar
  90. [103]103. El-Am E.A., Dispenzieri A., Melduni R.M., et al. Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis. J Am Coll Cardiol 2019;73:589-597. Go to Citation Crossref PubMed Google Scholar
  91. [104]104. Feng D., Syed I.S., Martinez M., et al. Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation 2009;119:2490-2497. Go to Citation Crossref PubMed Google Scholar
  92. [105]105. Crespo-Leiro M.G., Metra M., Lund L.H., et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2018;20:1505-1535. Go to Citation Crossref PubMed Google Scholar
  93. [106]106. Fang J.C., Ewald G.A., Allen L.A., et al. Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee. J Card Fail 2015;21:519-534. Go to Citation Crossref PubMed Google Scholar
  94. [107]107. Greenberg B., Fang J., Mehra M., et al. Advanced heart failure: trans-atlantic perspectives on the Heart Failure Association of the European Society of Cardiology position statement. Eur J Heart Fail 2018;20:1536-1539. Go to Citation Crossref PubMed Google Scholar
  95. [108]108. Hunt S.A., Abraham W.T., Chin M.H., et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009;53:e1-e90. Go to Citation Crossref PubMed Google Scholar
  96. [109]109. Yancy C.W., Jessup M., Bozkurt B., et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 2016;68:1476-1488. Go to Citation Crossref PubMed Google Scholar
  97. [110]110. Thomas R., Huntley A., Mann M., et al. Specialist clinics for reducing emergency admissions in patients with heart failure: a systematic review and meta-analysis of randomised controlled trials. Heart 2013;99:233-239. Go to Citation Crossref PubMed Google Scholar
  98. [111]111. Beckett N.S., Peters R., Fletcher A.E., et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887-1898. Go to Citation Crossref PubMed Google Scholar
  99. [113]113. Kostis J.B., Davis B.R., Cutler J., et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA 1997;278:212-216. Go to Citation Crossref PubMed Google Scholar
  100. [114]114. Staessen J.A., Fagard R., Thijs L., et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757-764. Go to Citation Crossref PubMed Google Scholar
  101. [115]115. Thomopoulos C., Parati G., Zanchetti A. Effects of blood pressure-lowering treatment. 6. Prevention of heart failure and new-onset heart failure--meta-analyses of randomized trials. J Hypertens 2016;34:373-384. Go to Citation Crossref PubMed Google Scholar
  102. [118]118. Butler J., Kalogeropoulos A.P., Georgiopoulou V.V., et al. Systolic blood pressure and incident heart failure in the elderly. The Cardiovascular Health Study and the Health, Ageing and Body Composition Study. Heart 2011;97:1304-1311. Go to Citation Crossref PubMed Google Scholar
  103. [119]119. Neal B., Perkovic V., Mahaffey K.W., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644-657. Go to Citation Crossref PubMed Google Scholar
  104. [120]120. Wiviott S.D., Raz I., Bonaca M.P., et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347-357. Go to Citation Crossref PubMed Google Scholar
  105. [122]122. Del Gobbo L.C., Kalantarian S., Imamura F., et al. Contribution of major lifestyle risk factors for incident heart failure in older adults: the Cardiovascular Health Study. J Am Coll Cardiol HF 2015;3:520-528. Go to Citation Google Scholar
  106. [123]123. Wang Y., Tuomilehto J., Jousilahti P., et al. Lifestyle factors in relation to heart failure among Finnish men and women. Circ Heart Fail 2011;4:607-612. Go to Citation Crossref PubMed Google Scholar
  107. [125]125. Hu G., Jousilahti P., Antikainen R., et al. Joint effects of physical activity, body mass index, waist circumference, and waist-to-hip ratio on the risk of heart failure. Circulation 2010;121:237-244. Go to Citation Crossref PubMed Google Scholar
  108. [126]126. Folsom A.R., Shah A.M., Lutsey P.L., et al. American Heart Association's Life's Simple 7: avoiding heart failure and preserving cardiac structure and function. Am J Med 2015;128:970-976.e972. Go to Citation Crossref PubMed Google Scholar
  109. [127]127. Tektonidis T.G., Åkesson A., Gigante B., et al. Adherence to a Mediterranean diet is associated with reduced risk of heart failure in men. Eur J Heart Fail 2016;18:253-259. Go to Citation Crossref PubMed Google Scholar
  110. [128]128. Levitan E.B., Wolk A., Mittleman M.A. Consistency with the DASH diet and incidence of heart failure. Arch Intern Med 2009;169:851-857. Go to Citation Crossref PubMed Google Scholar
  111. [129]129. Levitan E.B., Wolk A., Mittleman M.A. Relation of consistency with the dietary approaches to stop hypertension diet and incidence of heart failure in men aged 45 to 79 years. Am J Cardiol 2009;104:1416-1420. Go to Citation Crossref PubMed Google Scholar
  112. [130]130. Lara K.M., Levitan E.B., Gutierrez O.M., et al. Dietary patterns and incident heart failure in U.S. adults without known coronary disease. J Am Coll Cardiol 2019;73:2036-2045. Go to Citation Crossref PubMed Google Scholar
  113. [131]131. Ledwidge M., Gallagher J., Conlon C., et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA 2013;310:66-74. Go to Citation Crossref PubMed Google Scholar
  114. [133]133. Kannel W.B., D'Agostino R.B., Silbershatz H., et al. Profile for estimating risk of heart failure. Arch Intern Med 1999;159:1197-1204. Go to Citation Crossref PubMed Google Scholar
  115. [134]134. Butler J., Kalogeropoulos A., Georgiopoulou V., et al. Incident heart failure prediction in the elderly: the health ABC heart failure score. Circ Heart Fail 2008;1:125-133. Go to Citation Crossref PubMed Google Scholar
  116. [135]135. Agarwal S.K., Chambless L.E., Ballantyne C.M., et al. Prediction of incident heart failure in general practice: the Atherosclerosis Risk in Communities (ARIC) Study. Circ Heart Fail 2012;5:422-429. Go to Citation Crossref PubMed Google Scholar
  117. [136]136. SOLVD Investigators. Yusuf S., Pitt B., et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-691. Go to Citation Crossref PubMed Google Scholar
  118. [137]137. Jong P., Yusuf S., Rousseau M.F., et al. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 2003;361:1843-1848. Go to Citation Crossref PubMed Google Scholar
  119. [138]138. Afilalo J., Majdan A.A., Eisenberg M.J. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart 2007;93:914-921. Go to Citation Crossref PubMed Google Scholar
  120. [139]139. Heart Protection Study Collaborative Group. Emberson J.R., Ng L.L., et al. N-terminal pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. J Am Coll Cardiol 2007;49:311-319. Go to Citation Crossref PubMed Google Scholar
  121. [140]140. Preiss D., Campbell R.T., Murray H.M., et al. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. Eur Heart J 2015;36:1536-1546. Go to Citation Crossref PubMed Google Scholar
  122. [141]141. Scirica B.M., Morrow D.A., Cannon C.P., et al. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol 2006;47:2326-2331. Go to Citation Crossref PubMed Google Scholar
  123. [142]142. Strandberg T.E., Holme I., Faergeman O., et al. Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction. Am J Cardiol 2009;103:1381-1385. Go to Citation Crossref PubMed Google Scholar
  124. [143]143. Velazquez E.J., Pfeffer M.A., McMurray J.V., et al. VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. Eur J Heart Fail 2003;5:537-544. Go to Citation Crossref PubMed Google Scholar
  125. [144]144. Dargie H.J. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-1390. Go to Citation Crossref PubMed Google Scholar
  126. [145]145. Exner D.V., Dries D.L., Waclawiw M.A., et al. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the studies of left ventricular dysfunction. J Am Coll Cardiol 1999;33:916-923. Crossref PubMed Google Scholar a [...] blockers should be used to reduce mortality b [...] should be used to prevent symptomatic HF
  127. [146]146. Vantrimpont P., Rouleau J.L., Wun C.C., et al. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. J Am Coll Cardiol 1997;29:229-236. Crossref PubMed Google Scholar a [...] blockers should be used to reduce mortality b [...] should be used to prevent symptomatic HF
  128. [147]147. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-883. Go to Citation Crossref PubMed Google Scholar
  129. [148]148. Dargie H.J., Hildebrandt P.R., Riegger G.A., et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure. J Am Coll Cardiol 2007;49:1696-1704. Go to Citation Crossref PubMed Google Scholar
  130. [149]149. Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319:385-392. Go to Citation Crossref PubMed Google Scholar
  131. [150]150. Goldstein R.E., Boccuzzi S.J., Cruess D., et al. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation 1991;83:52-60. Go to Citation Crossref PubMed Google Scholar
  132. [152]152. Ponikowski P., van Veldhuisen D.J., Comin-Colet J., et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiencydagger. Eur Heart J 2015;36:657-668. Go to Citation Crossref PubMed Google Scholar
  133. [153]153. Beck-da-Silva L., Piardi D., Soder S., et al. IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia. Int J Cardiol 2013;168:3439-3442. Go to Citation Crossref PubMed Google Scholar
  134. [154]154. Ponikowski P., Kirwan B.A., Anker S.D., et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet 2020;396:1895-1904. Go to Citation Crossref PubMed Google Scholar
  135. [155]155. Swedberg K., Young J.B., Anand I.S., et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 2013;368:1210-1219. Go to Citation Crossref PubMed Google Scholar
  136. [156]156. Kang J., Park J., Lee J.M., et al. The effects of erythropoiesis stimulating therapy for anemia in chronic heart failure: a meta-analysis of randomized clinical trials. Int J Cardiol 2016;218:12-22. Go to Citation Crossref PubMed Google Scholar
  137. [157]157. Banach M., Bhatia V., Feller M.A., et al. Relation of baseline systolic blood pressure and long-term outcomes in ambulatory patients with chronic mild to moderate heart failure. Am J Cardiol 2011;107:1208-1214. Go to Citation Crossref PubMed Google Scholar
  138. [158]158. Lee T.T., Chen J., Cohen D.J., et al. The association between blood pressure and mortality in patients with heart failure. Am Heart J 2006;151:76-83. Go to Citation Crossref PubMed Google Scholar
  139. [159]159. Whelton P.K., Carey R.M., Aronow W.S., et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2018;71:e127-e248. Go to Citation Crossref PubMed Google Scholar
  140. [160]160. Arzt M., Schroll S., Series F., et al. Auto-servoventilation in heart failure with sleep apnoea: a randomised controlled trial. Eur Respir J 2013;42:1244-1254. Crossref PubMed Google Scholar a [...] quality and decrease daytime sleepiness b [...] between obstructive and central sleep apnea
  141. [161]161. O'Connor C.M., Whellan D.J., Fiuzat M., et al. Cardiovascular outcomes with minute ventilation-targeted adaptive servo-ventilation therapy in heart failure: the CAT-HF trial. J Am Coll Cardiol 2017;69:1577-1587. Go to Citation Crossref PubMed Google Scholar
  142. [162]162. Cowie M.R., Woehrle H., Wegscheider K., et al. Adaptive servo-ventilation for central sleep apnea in systolic heart failure. N Engl J Med 2015;373:1095-1105. Crossref PubMed Google Scholar a [...] quality and decrease daytime sleepiness b [...] adaptive servo-ventilation causes harm
  143. [164]164. Arzt M., Floras J.S., Logan A.G., et al. Suppression of central sleep apnea by continuous positive airway pressure and transplant-free survival in heart failure: a post hoc analysis of the Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure Trial (CANPAP). Circulation 2007;115:3173-3180. Go to Citation Crossref PubMed Google Scholar
  144. [165]165. Zannad F., Ferreira J.P., Pocock S.J., et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 2020;396:819-829. Go to Citation Crossref PubMed Google Scholar
  145. [166]166. Kato E.T., Silverman M.G., Mosenzon O., et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation 2019;139:2528-2536. Go to Citation Crossref PubMed Google Scholar
  146. [167]167. Mason P.K., Lake D.E., DiMarco J.P., et al. Impact of the CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation. Am J Med 2012;125:603e601-603e606. Go to Citation Crossref Google Scholar
  147. [169]169. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891. Crossref PubMed Google Scholar a [...] receive chronic anticoagulant therapy b [...] over warfarin in eligible patients
  148. [172]172. Ferreira J., Ezekowitz M.D., Connolly S.J., et al. Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial. Eur J Heart Fail 2013;15:1053-1061. Go to Citation Crossref PubMed Google Scholar
  149. [173]173. McMurray J.J., Ezekowitz J.A., Lewis B.S., et al. Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial. Circ Heart Fail 2013;6:451-460. Go to Citation Crossref PubMed Google Scholar
  150. [174]174. Siller-Matula J.M., Pecen L., Patti G., et al. Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: the PREFER in AF-HF substudy. Int J Cardiol 2018;265:141-147. Go to Citation Crossref PubMed Google Scholar
  151. [175]175. Magnani G., Giugliano R.P., Ruff C.T., et al. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48. Eur J Heart Fail 2016;18:1153-1161. Go to Citation Crossref PubMed Google Scholar
  152. [176]176. Savarese G., Giugliano R.P., Rosano G.M., et al. Efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation and heart failure: a meta-analysis. J Am Coll Cardiol HF 2016;4:870-880. Go to Citation Google Scholar
  153. [177]177. Di Biase L., Mohanty P., Mohanty S., et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation 2016;133:1637-1644. Go to Citation Crossref PubMed Google Scholar
  154. [178]178. Marrouche N.F., Brachmann J., Andresen D., et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 2018;378:417-427. Go to Citation Crossref PubMed Google Scholar
  155. [179]179. Chen S., Purerfellner H., Meyer C., et al. Rhythm control for patients with atrial fibrillation complicated with heart failure in the contemporary era of catheter ablation: a stratified pooled analysis of randomized data. Eur Heart J 2020;41:2863-2873. Go to Citation Crossref PubMed Google Scholar
  156. [180]180. Packer D.L., Piccini J.P., Monahan K.H., et al. Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial. Circulation 2021;143:1377-1390. Go to Citation Crossref PubMed Google Scholar
  157. [182]182. Brignole M., Menozzi C., Gianfranchi L., et al. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation: a randomized, controlled study. Circulation 1998;98:953-960. Go to Citation Crossref PubMed Google Scholar
  158. [183]183. Doshi R.N., Daoud E.G., Fellows C., et al. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol 2005;16:1160-1165. Go to Citation Crossref PubMed Google Scholar
  159. [184]184. Brignole M., Gammage M., Puggioni E., et al. Comparative assessment of right, left, and biventricular pacing in patients with permanent atrial fibrillation. Eur Heart J 2005;26:712-722. Go to Citation Crossref PubMed Google Scholar
  160. [185]185. Brignole M., Botto G., Mont L., et al. Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial. Eur Heart J 2011;32:2420-2429. Go to Citation Crossref PubMed Google Scholar
  161. [186]186. Brignole M., Pokushalov E., Pentimalli F., et al. A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS. Eur Heart J 2018;39:3999-4008. Go to Citation Crossref PubMed Google Scholar
  162. [187]187. Chatterjee N.A., Upadhyay G.A., Ellenbogen K.A., et al. Atrioventricular nodal ablation in atrial fibrillation: a meta-analysis of biventricular vs. right ventricular pacing mode. Eur J Heart Fail 2012;14:661-667. Go to Citation Crossref PubMed Google Scholar
  163. [188]188. Prabhu S., Taylor A.J., Costello B.T., et al. Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction: the CAMERA-MRI study. J Am Coll Cardiol 2017;70:1949-1961. Go to Citation Crossref PubMed Google Scholar
  164. [189]189. Freudenberger R.S., Hellkamp A.S., Halperin J.L., et al. Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HEFT). Circulation 2007;115:2637-2641. Go to Citation Crossref PubMed Google Scholar
  165. [190]190. Camm A.J., Kirchhof P., Lip G.Y., et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-2429. Go to Citation Crossref PubMed Google Scholar
  166. [191]191. Melgaard L., Gorst-Rasmussen A., Lane D.A., et al. Assessment of the CHA2DS2-VASc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation. JAMA 2015;314:1030-1038. Go to Citation Crossref PubMed Google Scholar
  167. [192]192. Mogensen U.M., Jhund P.S., Abraham W.T., et al. Type of atrial fibrillation and outcomes in patients with heart failure and reduced ejection fraction. J Am Coll Cardiol 2017;70:2490-2500. Go to Citation Crossref PubMed Google Scholar
  168. [193]193. Caracciolo E.A., Davis K.B., Sopko G., et al. Comparison of surgical and medical group survival in patients with left main equivalent coronary artery disease. Long-term CASS experience. Circulation 1995;91:2335-2344. Go to Citation Crossref PubMed Google Scholar
  169. [194]194. Howlett J.G., Stebbins A., Petrie M.C., et al. CABG improves outcomes in patients with ischemic cardiomyopathy: 10-year follow-up of the STICH Trial. J Am Coll Cardiol HF 2019;7:878-887. Go to Citation Google Scholar
  170. [195]195. Mark D.B., Knight J.D., Velazquez E.J., et al. Quality-of-life outcomes with coronary artery bypass graft surgery in ischemic left ventricular dysfunction: a randomized trial. Ann Intern Med 2014;161:392-399. Go to Citation Crossref PubMed Google Scholar
  171. [196]196. Park S., Ahn J.M., Kim T.O., et al. Revascularization in patients with left main coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol 2020;76:1395-1406. Go to Citation Crossref PubMed Google Scholar
  172. [197]197. Petrie M.C., Jhund P.S., She L., et al. Ten-year outcomes after coronary artery bypass grafting according to age in patients with heart failure and left ventricular systolic dysfunction: an analysis of the extended follow-up of the STICH Trial (Surgical Treatment for Ischemic Heart Failure). Circulation 2016;134:1314-1324. Go to Citation Crossref PubMed Google Scholar
  173. [198]198. Tam D.Y., Dharma C., Rocha R., et al. Long-term survival after surgical or percutaneous revascularization in patients with diabetes and multivessel coronary disease. J Am Coll Cardiol 2020;76:1153-1164. Go to Citation Crossref PubMed Google Scholar
  174. [199]199. Velazquez E.J., Lee K.L., Deja M.A., et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 2011;364:1607-1616. Go to Citation Crossref PubMed Google Scholar
  175. [200]200. Velazquez E.J., Lee K.L., Jones R.H., et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med 2016;374:1511-1520. Go to Citation Crossref PubMed Google Scholar
  176. [201]201. Wang S.Y., Long J.B., Hurria A., et al. Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival. Breast Cancer Res Treat 2014;146:411-419. Go to Citation Crossref PubMed Google Scholar
  177. [202]202. Guarneri V., Lenihan D.J., Valero V., et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 2006;24:4107-4115. Crossref PubMed Google Scholar a [...] is recommended to improve management b [...] to HF and improve cardiac function c [...] and guide the choice of cancer therapy d [...] of drug-induced cardiomyopathy
  178. [203]203. Cardinale D., Colombo A., Lamantia G., et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010;55:213-220. Go to Citation Crossref PubMed Google Scholar
  179. [204]204. Cardinale D., Colombo A., Bacchiani G., et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015;131:1981-1988. Crossref PubMed Google Scholar a [...] to HF and improve cardiac function b [...] of drug-induced cardiomyopathy
  180. [205]205. Chavez-MacGregor M., Zhang N., Buchholz T.A., et al. Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol 2013;31:4222-4228. Go to Citation Crossref PubMed Google Scholar
  181. [207]207. Armenian S.H., Sun C.L., Shannon T., et al. Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation. Blood 2011;118:6023-6029. Go to Citation Crossref PubMed Google Scholar
  182. [208]208. Henry M.L., Niu J., Zhang N., et al. Cardiotoxicity and cardiac monitoring among chemotherapy-treated breast cancer patients. J Am Coll Cardiol Img 2018;11:1084-1093. Crossref Google Scholar a [...] and guide the choice of cancer therapy b [...] of drug-induced cardiomyopathy
  183. [209]209. Wang L., Tan T.C., Halpern E.F., et al. Major cardiac events and the value of echocardiographic evaluation in patients receiving anthracycline-based chemotherapy. Am J Cardiol 2015;116:442-446. Go to Citation Crossref PubMed Google Scholar
  184. [210]210. Seferina S.C., de Boer M., Derksen M.W., et al. Cardiotoxicity and cardiac monitoring during adjuvant trastuzumab in daily Dutch practice: a study of the Southeast Netherlands Breast Cancer Consortium. Oncologist 2016;21:555-562. Go to Citation Crossref PubMed Google Scholar
  185. [211]211. Abu-Khalaf M.M., Safonov A., Stratton J., et al. Examining the cost-effectiveness of baseline left ventricular function assessment among breast cancer patients undergoing anthracycline-based therapy. Breast Cancer Res Treat 2019;176:261-270. Go to Citation Crossref PubMed Google Scholar
  186. [212]212. Truong S.R., Barry W.T., Moslehi J.J., et al. Evaluating the utility of baseline cardiac function screening in early-stage breast cancer treatment. Oncologist 2016;21:666-670. Go to Citation Crossref PubMed Google Scholar
  187. [213]213. Jeyakumar A., DiPenta J., Snow S., et al. Routine cardiac evaluation in patients with early-stage breast cancer before adjuvant chemotherapy. Clin Breast Cancer 2012;12:4-9. Go to Citation Crossref PubMed Google Scholar
  188. [214]214. Steuter J., Bociek R., Loberiza F., et al. Utility of prechemotherapy evaluation of left ventricular function for patients with lymphoma. Clin Lymphoma Myeloma Leuk 2015;15:29-34. Go to Citation Crossref PubMed Google Scholar
  189. [215]215. Conrad A.L., Gundrum J.D., McHugh V.L., et al. Utility of routine left ventricular ejection fraction measurement before anthracycline-based chemotherapy in patients with diffuse large B-cell lymphoma. J Oncol Pract 2012;8:336-340. Go to Citation Crossref PubMed Google Scholar
  190. [216]216. O'Brien P., Matheson K., Jeyakumar A., et al. The clinical utility of baseline cardiac assessments prior to adjuvant anthracycline chemotherapy in breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat 2019;174:357-363. Go to Citation Crossref PubMed Google Scholar
  191. [217]217. Akpek M., Ozdogru I., Sahin O., et al. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail 2015;17:81-89. Go to Citation Crossref PubMed Google Scholar
  192. [218]218. Avila M.S., Ayub-Ferreira S.M., de Barros Wanderley M.R. Jr., et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial. J Am Coll Cardiol 2018;71:2281-2290. Go to Citation Crossref PubMed Google Scholar
  193. [219]219. Bosch X., Rovira M., Sitges M., et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol 2013;61:2355-2362. Go to Citation Crossref PubMed Google Scholar
  194. [220]220. Cardinale D., Colombo A., Sandri M.T., et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006;114:2474-2481. Go to Citation Crossref PubMed Google Scholar
  195. [221]221. Guglin M., Krischer J., Tamura R., et al. Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. J Am Coll Cardiol 2019;73:2859-2868. Go to Citation Crossref PubMed Google Scholar
  196. [222]222. Gulati G., Heck S.L., Ree A.H., et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 2016;37:1671-1680. Go to Citation Crossref PubMed Google Scholar
  197. [223]223. Kalay N., Basar E., Ozdogru I., et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006;48:2258-2262. Go to Citation Crossref PubMed Google Scholar
  198. [224]224. Pituskin E., Mackey J.R., Koshman S., et al. Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J Clin Oncol 2017;35:870-877. Go to Citation Crossref PubMed Google Scholar
  199. [225]225. Shah P., Garris R., Abboud R., et al. Meta-analysis comparing usefulness of beta blockers to preserve left ventricular function during anthracycline therapy. Am J Cardiol 2019;124:789-794. Go to Citation Crossref PubMed Google Scholar
  200. [226]226. Cardinale D., Ciceri F., Latini R., et al. Anthracycline-induced cardiotoxicity: a multicenter randomised trial comparing two strategies for guiding prevention with enalapril: the International CardioOncology Society-one trial. Eur J Cancer 2018;94:126-137. Go to Citation Crossref PubMed Google Scholar

200 of 206 shown

Cited by

Sorted by citations

Authors
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., Fang, J. C., Fedson, S. E., Fonarow, G. C., Hayek, S. S., Hernandez, A. F., Khazanie, P., Kittleson, M. M., Lee, C. S., Link, M. S., Milano, C. A., Nnacheta, L. C., Sandhu, A. T., Stevenson, L. W., Vardeny, O., Vest, A. R., & Yancy, C. W.
ORCID
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2022-05
Volume
79
Issue
17
Pages
1757-1780
ISSN
0735-1097 (ISSN-L)
DOI
10.1016/j.jacc.2021.12.011
OpenAlex
W4220668577
Cited by
931
References
22
Citations by year
2026: 162 · 2025: 228 · 2024: 236 · 2023: 236 · 2022: 68
FWCI
133.71
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of the American College of Cardiology (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Heart, Lung, and Blood Institute (K23HL145122)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
Keywords
heart failure, heart failure treatment, heart failure diagnosis, heart failure prevention, guideline recommendations, evidence-based treatment, quality of care
MeSH terms
American Heart Association, Cardiology, Cardiovascular System, Heart Failure, Humans, United States

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review